SecBot SecBot
8-K ·Filed Sep 14, 2026

QTTB

Q32 Bio Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed2mo ago SEC0001193125-26-389836
8-K context-dependent: Items 7.01, 8.01
Actionable Insight • Neutral

Monitor Q32 Bio for the initiation of the registration-directed trial for bempikibart in alopecia areata, expected in the first half of 2027. The next key catalyst will be data readouts from the SIGNAL-AA program. The executive hires add credibility but do not change the near-term risk/reward profile.

DirectionNeutral
Confidencehigh
Horizonmonths

bempikibart

◆ Mixed Named in this 8-K
Impact
Phase
Phase 2
Time to market
At least 3-5 years. Registration-directed (Phase 3) program expected to begin in H1 2027; typical Phase 3 + FDA review takes 3-4 years from initiation.
Next catalyst
None dated

What to watchThe July 13 positive Phase 2a data has already been priced in (~60% single-day surge). The next meaningful catalyst is the start of a Phase 3 registration program in H1 2027, but that is a process milestone, not a binary event. Investors should watch for FDA feedback on the registration-directed plan, potential partnership interest given the clean safety profile, and additional financing rounds as Q32 Bio will need capital to fund the pivotal trials.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$10.91
T+0 close · Sep 14, 2026 · via day close
Latest settled
−19.89%
T+20 · $8.74 · next T+60 in 21d
Vs SPY
−22.15%
α at T+20
Latest observation
+7.67%
T+44 · FF3 residual α
  1. T+0 · Sep 14 $10.91entry
  2. T+1 · 2mo ago +2.38%α +2.84% · $11.17
  3. T+5 · 8w ago −4.03%α −4.14% · $10.47
  4. T+20 · 5w ago −19.89%α −22.15% · $8.74
  5. T+45 · todayOpen
  6. T+60 · in 21d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Q32 Bio announced the appointment of Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer, both with strong late-stage development and regulatory backgrounds. The hires signal the company's transition toward a registration-directed program for bempikibart in alopecia areata, with a registrational trial expected in the first half of 2027. This is a routine executive appointment with no financial data or material business changes disclosed, making it a neutral event for traders.

Key Facts

  • Q32 Bio appointed Dr. José Trevejo as Chief Medical Officer and Dr. Ellie Hershberger as Chief Development Officer on September 14, 2026.
  • Dr. Trevejo previously served as CMO at Tarsus Pharmaceuticals, where he helped lead the FDA approval and launch of XDEMVY.
  • Dr. Hershberger previously served as CDO at Adagio Therapeutics (now Invivyd), contributing to its IPO that raised approximately $356 million in gross proceeds.
  • The company plans to advance bempikibart into a registration-directed program for severe or very severe alopecia areata in the first half of 2027.
  • No financial figures, guidance, or material business changes were disclosed in this filing.

Financial Impact

No financial impact disclosed in this filing.

Risk Factors

  • Clinical trial risk for bempikibart in alopecia areata
  • Capital requirements to fund registration-directed program
  • Competition from existing and emerging alopecia areata therapies

Market Snapshot

Exchange
CBOE
Analyst Consensus
92% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-389836
Document: d158730dex991.htm0001193125-26-389836
Document: 0001193125-26-389836-index-headers.html0001193125-26-389836
Document: 0001193125-26-389836-index.html0001193125-26-389836
Document: 0001193125-26-389836.txt0001193125-26-389836

Track record

23 reports on QTTB

Performance horizon

3 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +48.47% at T+60 after the Jul 14, 2026 report. 6 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $8.29 Now $8.29 −0.00% settles Dec 16
  2. Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.47 Now $8.29 −2.13% settles Dec 15
  3. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $8.71 Now $8.29 −4.82% settles Dec 15
  4. Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
  5. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $9.34 Now $8.29 −11.24% settles Dec 8
  6. Nov 4, 202612d ago 8-K Neutral 4/10 Entry $8.97 Now $8.29 −7.58% settles Dec 3
  7. Oct 28, 202619d ago SC 13G Neutral 4/10 Entry $9.06 Now $8.29 −8.50% settles Nov 25
  8. Oct 9, 20265w ago SC 13G Neutral 4/10 Entry $8.74 to $9.36 Now $8.29 −5.15% ▲ +7.09% +10.36% vs SPY
  9. Sep 30, 20266w ago 8-K Bullish 6/10 Entry $8.27 to $8.71 Now $8.29 +0.24% ▲ +5.32% +4.05% vs SPY
  10. Sep 14, 20269w ago 8-K Neutral 3/10 Viewing Entry $10.91 to $8.74 Now $8.29 −24.01% ▼ −19.89% −22.15% vs SPY
Showing 10 of 23

US Market Status

Market Closed · Opens in 6h 35m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 14, 2026